Teriparatide: A review

Clinical Therapeutics

Volumn 26, Issue 6, 2004, Pages 841-854

  Quattrocchi, Elaena ^a   Kourlas, Helen ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

bone formation; osteoporosis; teriparatide

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; DIGITALIS; DIGOXIN; ESTROGEN; FLUORIDE; FUROSEMIDE; GROWTH FACTOR; HYDROCHLOROTHIAZIDE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM;

ANGINA PECTORIS; ASTHENIA; BONE DENSITY; BONE MINERAL; BONE TUMOR; CARCINOGENESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; FEMUR NECK; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPERURICEMIA; INSOMNIA; LEG CRAMP; LUMBAR SPINE; MEDLINE; MORBIDITY; NAUSEA; NECK PAIN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE; PREGNANCY; REVIEW; STATISTICAL SIGNIFICANCE; SYNCOPE; VERTIGO;

EID: 3242661064     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90128-2     Document Type: Article

References (39)

1. National Institutes of Health. Osteoporosis and Related Bone Diseases - National Resource Center. Osteoporosis. August 13, 2003;. Available at: http://www.nof.org/osteoporosis/index.htm:August 13, 2003;. Accessed
2. Crandall C. Osteoporosis. A two article symposium. Postgrad Med. 114:2003;21-32
3. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 285:2001;785-795
4. Steinweg K.K. Osteoporosis. 2nd ed. Rakel R.E. Saunders Manual of Medical Practice. 2000;928-931 WB Saunders, Philadelphia, Pa
5. Rubin M.R., Bilezikian J.P. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am. 32:2003;285-307
6. Simonelli C. Parathyroid hormone: A new treatment option for osteoporosis. Pharmacy and Therapeutics. 27:2002;410-413
7. Forteo. (teriparatide [rDNA origin] injection) [package insert]. Product Information. 2002;Eli Lilly and Co, Indianapolis, Ind
8. Bringhurst F.R., Demay M.B., Kronenberg H.M., et al. Hormones and disorders of mineral metabolism. 9th ed. Wilson J.D. Williams Textbook of Endocrinology. 1998;1155-1210 WB Saunders, Philadelphia, Pa
9. Tashjian A.H. Jr., Chabner B.A. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 17:2002;1151-1161
10. Rosen C.J., Bilezikian J.P. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 86:2001;957-964
11. Honeywell M., Phillips S., Branch E., et al. Teriparatide for osteoporosis: A clinical review. Pharmacy and Therapeutics. 28:2003;713-716
12. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:2001;1434-1441
13. Zanchetta J.R., Bogado C.E., Ferretti J.L., et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 18:2003;539-543
14. Cosman F., Nieves J., Woelfert L., et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res. 13:1998;1051-1055
15. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 350:1997;550-555
16. Roe E.B., Sanchez S.D., Del-Puerto G.A., et al. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis: Results from a placebo controlled randomized trial. J Bone Miner Res. 14:1999;S137
17. Cosman F., Nieves J., Woelfert L., et al. Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 16:2001;925-931
18. Lane N.E., Sanchez S., Modin G.W., et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res. 15:2000;944-951
19. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 102:1998;1627-1633
20. Rehman Q., Lang T.F., Arnaud C.D., et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int. 14:2003;77-81
21. Crandell C. Review: Parathyroid hormone increases lumbar spine bone mineral density and decreases vertebral fractures in osteoporosis. ACP J Club. 139:2003;11
22. Rittmaster R.S., Bolognese M., Ettinger M.P., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 85:2000;2129-2134
23. Brown S.A., Rosen C.J. Osteoporosis. Med Clin North Am. 87:2003;1039-1063
24. Body J.J., Gaich G.A., Scheele W.H., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 87:2002;4528-4535
25. Campion J.M., Maricic M.J. Osteoporosis in men. Am Fam Physician. 67:2003;1521-1526
26. Kurland E.S., Cosman F., McMahon D.J., et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 85:2000;3069-3076
27. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 18:2003;9-17
28. Levin R.H. Pediatric and neonatal therapy. 7th ed. Herfindal E.T., Gourley D.R. Textbook of Therapeutics. Drug and Disease Management. 2000;1955-1968 Lippincott Williams & Wilkins, Philadelphia, Pa
29. Koch C.A. Rapid increase in bone mineral density in a child with osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34. Exp Clin Endocrinol Diabetes. 110:2002;100
30. Koch C.A. Rapid increase in bone mineral density in a child with osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34. Exp Clin Endocrinol Diabetes. 109:2001;350-354
31. Patel S.R., Benjamin R.S. Soft tissue and bone sarcomas and bone metastases. Braunwald E. Harrison's Principles of Internal Medicine. 15th ed.:2001;625-628 McGraw-Hill, New York, NY
32. Arndt C., Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 341:1999;342-352
33. White L.M., Kandel R. Osteoid-producing tumors of bone. Semin Musculoskelet Radiol. 4:2000;25-43
34. Benson C.T., Voelker J.R. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clin Pharmacol Ther. 73:2003;87-94
35. Hansen M.F., Nellissery M.J., Bhatia P. Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res. 14:(Suppl 2):1999;39-44
36. Krane S.M., Schiller A.L. Paget's disease and other dysplasias of bone. Braunwald E. Harrison's Principles of Internal Medicine. 15th ed.:2001;2237-2245 McGraw-Hill, New York, NY
37. Deal C., Gideon J. Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis. Cleve Clin J Med. 70:2003;585-586
38. Deal C., Gideon J. Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis. Cleve Clin J Med. 70:2003;589-590
39. Deal C., Gideon J. Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis. Cleve Clin J Med. 70:2003;592-594